⌕
Opko Health · OPK · Nasdaq
Tenet 43 · Weak
Compare
$1.620.00%At closeTenet 43 · Weak
$1.620.00 (0.00%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Opko Health (OPK) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is OPK's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 5, 2026 · 01:18 ET
What OPKO Health (OPK) Said on Its Q3 Earnings Call

OPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference asse…

OPK 0.0% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 00:06 ET
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript

OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 20:52 ET
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates

OPKO Health (OPK) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.03 per share a year ago.…

OPK 0.0% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:23 ETCOMPANY'S OWN WORDS
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results

MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026.…

OPK 0.0% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 08:52 ETCOMPANY'S OWN WORDS
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 o…

OPK 0.0% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 08:00 ET
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly

KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of …

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 12:20 ET
OPKO Health to Sell Select BioReference Assets to Labcorp for $722M

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.…

OPK 0.0% todayRead at source ↗
● BenzingaOct 15, 2026 · 11:41 ET
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.…

OPK 0.0% todayRead at source ↗
● PRNewsWireOct 15, 2026 · 07:30 ET
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.…

OPK 0.0% todayRead at source ↗
● Defense WorldOct 7, 2026 · 08:17 ET
Comparing Ardent Health (NYSE:ARDT) & OPKO Health (NASDAQ:OPK)

Ardent Health (NYSE: ARDT - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength…

OPK 0.0% todayRead at source ↗
● Defense WorldOct 3, 2026 · 04:28 ET
OPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are presently covering the company, MarketBeat.com reports. One investment analy…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchSep 28, 2026 · 12:55 ET
Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchSep 21, 2026 · 10:35 ET
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.…

OPK 0.0% todayRead at source ↗
● MarketBeatSep 11, 2026 · 01:02 ET
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical program…

OPK 0.0% todayRead at source ↗
● Defense WorldSep 9, 2026 · 04:34 ET
Analyzing HCA Healthcare (NYSE:HCA) & OPKO Health (NASDAQ:OPK)

HCA Healthcare (NYSE: HCA - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of the…

OPK 0.0% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 13:55 ETCOMPANY'S OWN WORDS
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, tod…

OPK 0.0% todayRead at source ↗
● Defense WorldSep 1, 2026 · 04:28 ET
Connor Clark & Lunn Investment Management Ltd. Invests $618,000 in OPKO Health, Inc. $OPK

Connor Clark and Lunn Investment Management Ltd. acquired a new stake in OPKO Health, Inc. (NASDAQ: OPK) in a recent quarter, according to the company in its most recent filing with the SEC. The fund acquired 412,051 sha…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchAug 26, 2026 · 12:31 ET
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchAug 24, 2026 · 12:16 ET
Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchAug 19, 2026 · 13:51 ET
OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchAug 19, 2026 · 13:41 ET
Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchAug 19, 2026 · 13:36 ET
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.…

OPK 0.0% todayRead at source ↗
● Zacks Investment ResearchAug 18, 2026 · 14:26 ET
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.…

OPK 0.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA36−0.4%
INTC4−0.5%
LAW4−8.6%
ABR3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just OPK · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.